Addendum to the guideline on the peri-operative management of anticoagulation and antiplatelet therapy
(British Journal of Haematology. 2016;175:602-613)

Dr Khalid Saja¹, on behalf of the Haemostasis and Thrombosis Taskforce of the British Society for Haematology

Authors’ affiliations:
¹ Haematology Department, Colchester General Hospital, East Suffolk and North Essex NHS Foundation Trust

Correspondence:
BSH Administrator, British Society for Haematology, 100 White Lion Street, London, N1 9PF, UK. E-mail: bshguidelines@b-s-h.org.uk

Keywords: CrCl, DOAC, interruption, peri-operative, procedure
Direct Oral Anticoagulants

So far, the peri-operative/peri-procedural management of the direct oral anticoagulants (DOACs) has largely been guided by pharmacokinetic data, with recommended periods of drug interruption based on drug-specific half-lives, an individual’s renal function, and the assessment of operative or procedural bleeding risk.

The Perioperative Anticoagulation Use for Surgery Evaluation (PAUSE) study prospectively enrolled 3007 patients with atrial fibrillation receiving anticoagulation with a DOAC (apixaban 41.8%, rivaroxaban 36%, dabigatran 22.2%), who were planned to have an elective procedure/surgery that required anticoagulation interruption. The study used a simplified and standardised management protocol (see figure below). Patients undergoing a low bleeding risk procedure omitted the DOAC for one day prior to the procedure (i.e. last dose to be taken at least 36 hours prior to procedure), and those undergoing a high bleeding risk procedure omitted the DOAC for 2 days (i.e. last dose to be taken at least 60 hours prior to procedure). Due to its almost exclusive renal elimination, patients on dabigatran who had a creatinine clearance (CrCl) of < 50mL/min had double the period of pre-procedural interruption (i.e. 2 days and 4 days for low and high bleeding risk procedures respectively). DOACs were resumed one day after a low bleeding risk procedure and 2-3 days after a high bleeding risk procedure. Bridging with heparin was not employed prior to the procedure, although post-procedural use of prophylactic heparin was permitted in patients at high risk of venous thromboembolism until DOAC resumption.

![Table showing peri-operative DOAC management](image-url)

- DOAC may be taken or administered

Procedures classified as high risk included 230 patients (7.6%) who had neuraxial anaesthesia. Both 30-day rates of major bleeding (apixaban 1.35%, dabigatran 0.90%, rivaroxaban 1.85%) and arterial thromboembolic events (apixaban 0.16%, dabigatran 0.60%, rivaroxaban 0.37%) were low. Pre-operative residual DOAC drug levels were measured in 2541 patients (84.5%). Almost 99% of patients undergoing a high bleeding risk procedure had drug levels below 50ng/mL, and over 85% had levels below 30ng/mL.

Recommendations:
- For direct Xa inhibitors, omit the anticoagulant for one day prior to low bleeding risk procedures and for 2 days prior to high bleeding risk procedures (1C).
- In patients with CrCl of ≥ 50mL/min, omit dabigatran for one day prior to low bleeding risk procedures and 2 days prior to high bleeding risk procedures (1C).
- In patients with CrCl < 50mL/min, omit dabigatran for 2 days prior to low bleeding risk procedures and for 4 days prior to high bleeding risk procedures (1C).
- Resume the DOAC one day after a low bleeding risk procedure and 2-3 days after a high bleeding risk procedure. Consider daily prophylactic heparin for patients at high risk of venous thrombosis prior to DOAC recommencement (2C).

Peri-operative Reversal of Direct Xa Inhibitors with Andexanet Alfa
Currently, there is no evidence to support the use of andexanet alfa for the reversal of these anticoagulants in the setting of elective or emergency surgery. The recommendation in the guideline that andexanet alfa should be used for anticoagulation reversal in the peri-operative setting is withdrawn.

Disclaimer
While the advice and information in this addendum is believed to be true and accurate at the time of going to press, neither the author(s), the BSH nor the publishers accept any legal responsibility for the content of this addendum.
References: